Econazole is a known inhibitor of CYP3A4/2C9. Due to the limited systemic availability after vaginal application (see Pharmacology: Pharmacokinetics under Actions), clinically relevant interactions are unlikely to occur, but have been reported with oral anticoagulants. In patients taking oral anticoagulants, such as warfarin or acenocoumarol, caution should be exercised and the anticoagulant effect should be monitored.
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Manage Account
Change Password
Sign Out
